R&D Capabilities

Our efforts are dedicated to providing trusted products and technologies for patients with serious immunologic and neurologic diseases, such as primary and secondary immunodeficiencies (PID and SID) and chronic inflammatory demyelinating polyneuropathy (CIDP). In addition, we are assessing the use of inhaled immunoglobulin for patients with bronchiectasis to enhance our respiratory portfolio, alongside our existing product ZEMAIRA^®/RESPREEZA^® for alpha-1 antitrypsin deficiency. Building on our legacy of delivering reliable, life-sustaining products, the Immunoglobulin TA is committed to advancing integrated and convenient approaches, guided by the voices of our patients.

CSL remains focused on easing the burden of disease and improving the lives of patients with rare bleeding disorders and benign hematological conditions. Significant progress was achieved in recent years in the treatment of haemophilia A and B through the introduction of innovative recombinant coagulation factors. More recently CSL gained approval of the first gene therapy for haemophilia B, HEMGENIX^®. CSL has deployed research efforts to develop therapeutic options for patients with sickle cell disease, a patient population with a high unmet medical need. We are focused on both acute treatment of vaso-occlusive crises and effective prophylaxis to reduce the frequency of sickle-cell related events. Additionally, we are undertaking exciting research efforts to advance innovative therapeutics in benign hematology conditions with unmet medical need, specifically in the areas of hemostasis and thrombosis.
There is a worldwide trend towards reasonable patient blood management (PBM) that includes the replacement of allogeneic blood product transfusions by coagulation factor concentrates wherever they are available. In keeping with CSL’s vast history in the area of coagulation factor concentrates, efforts are ongoing to ensure availability of fibrinogen and prothrombin factor concentrates during surgical procedures with high risk of major bleeding. In addition, the PBM includes focus on IV iron therapy for pre-/post-operative anemia management.

The cardiovascular and renal therapeutic area is focused on improving and extending the lives of patients with cardiovascular and renal diseases through our marketed products and development programs. Cardiovascular disease (CVD) is the primary cause of morbidity and mortality in patients with chronic kidney disease, particularly those with advanced CKD stages (4-5) who have a markedly elevated risk for CVD. The 3-year rate of major adverse cardiac events (cardiovascular death, myocardial infarction, stroke) in patients undergoing hemodialysis is approximately 25%, almost 3-fold higher than observed in patients with cardiovascular disease not on dialysis. CSL is developing Clazakizumab (an anti-IL6 antibody) for the prevention of cardiovascular morbidity and mortality in patients with end stage renal disease. In addition, there is an urgent need to develop novel therapies that preserve kidney function and delay, or avoid, dialysis. We are proud to offer TAVNEOS^® and FILSPARI^® to help patients with rare renal diseases.

We continue to build on our strong more than 40-year legacy in hereditary angioedema (HAE) as we work to expand our current medicines to provide optimal treatments for the full range of HAE patients, including our recombinant monoclonal antibody, ANDEMBRY®.
Our efforts also focus on developing treatments for select autoimmune indications with high unmet need, particularly those driven by pathomechanisms that play a fundamental role in the pathogenesis of autoimmune and alloimmune diseases. 
Autoimmune diseases are chronic, complex conditions resulting from a loss of self-tolerance, and CSL is committed to building and growing our autoimmune portfolio to bring innovative treatments to patients.

Advancing vaccines for the benefit of public health is a strategic priority for CSL. With a focus on expanding beyond influenza and progressing our current technologies, our first non-influenza vaccine, the sa-mRNA COVID-19 vaccine, KOSTAIVE^® was recently approved in Japan.

Additionally, CSL is further advancing cell based manufacturing technology in products such as aTIVc (adjuvanted trivalent influenza vaccine), vaccines containing CSL’s MF59^® adjuvant as well as developing the messenger RNA (mRNA) platform, targeting viruses of both seasonal and pandemic potential.